Drug details

Tyvaso DPI (treprostinil inhalation powder)

type of PAH, Prostacyclin Analogs

Tyvaso DPI (treprostinil) is a prostacyclin mimetic indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) and pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability.

This drug may have the following side effects:

• nausea,
• headache,
• cough,
• shortness of breath, and
• flushing,
• sore throat/mouth pain,
• lightheadedness/fainting.

The following drugs are related to Tyvaso DPI, either as a replacement or used together:

• Adcirca (tadalafil tablets)
• Alyq (tadalafil tablets)
• Letairis (ambrisentan tablets)
• Tracleer (bosentan)
• Lanoxin Injection (digoxin injection)
• Lanoxin (digoxin tablets)
• Veletri (epoprostenol powder for intravenous administration)
• Flolan (epoprostenol sodium)
• Ventavis (iloprost)
• Liqrev (sildenafil oral suspension)
• Remodulin (treprostinil sodium)
• Revatio (sildenafil citrate)
• Tadliq (tadalafil oral suspension)
• Tyvaso (treprostinil inhalation solution)
• Uptravi (uptravi selexipag tablets)